US4233303A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Xanthine derivatives
Assignee: Draco AB
•
Filing: 1978-09-29
•
Granted: 1980-11-11
•
Expires: 1998-09-29
Abstract
Abstract Compounds of the formula ##STR1## or physiologically acceptable salts thereof in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR2## methods for the preparation thereof; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof in the treatment of allergy and bronchial asthma.
Inventors
- 👤 Sten H. A. M. Bergstrand
- 👤 Per G. Kjellin
- 👤 Carl G. A. Persson
- 👤 Lars M. Sorenby
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 13:05
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/52; C07D239/54; C07D239/545; A; A61; A61P; A61P37/00; A61P37/08; C07D473/00; C07D473/02; C07D473/04; C07D473/06
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
33 words
A compound of the formula ##STR20## or a physiologically acceptable salt thereof, in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR21##
Claim 2
Dependent Claim
33 words
A compound of the formula ##STR20## or a physiologically acceptable salt thereof, in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR21##
Claim 3
Dependent Claim
31 words
A compound according to claim 1 with the formula ##STR22## or a physiologically acceptable salt thereof, wherein R 1 is methyl, ethyl or n-propyl and R 2 is methyl or n-propyl.
Claim 4
Dependent Claim
18 words
A compound according to claim 1 or 2 with the formula ##STR23## or a physiologically acceptable salt thereof.
Claim 5
Dependent Claim
31 words
A compound according to claim 1 with the formula ##STR24## or a physiologically acceptable salt thereof, wherein R 1 is methyl, ethyl or n-propyl and R 2 is methyl or n-propyl.
Claim 6
Dependent Claim
13 words
A compound according to claim 4 in the form of a racemic mixture.
Claim 7
Dependent Claim
14 words
A compound according to claim 4 in the form of a substantially pure stereoisomer.
Claim 8
Dependent Claim
63 words
A pharmaceutical preparation comprising as active ingredient an antianaphylactic effective amount of a compound of the formula ##STR25## or a physiologically acceptable salt or an optical isomer thereof, in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR26## in association with a pharmaceutically acceptable carrier for use in the treatment of allergy.
Claim 9
Dependent Claim
63 words
A pharmaceutical preparation comprising as active ingredient an antianaphylactic effective amount of a compound of the formula ##STR25## or a physiologically acceptable salt or an optical isomer thereof, in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR26## in association with a pharmaceutically acceptable carrier for use in the treatment of allergy.
Claim 10
Dependent Claim
31 words
A pharmaceutical preparation according to claim 7, comprising as active ingredient a compound according to any of claims 2, 3, 4, 5 or 6 in association with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
15 words
A pharmaceutical preparation according to any of claims 7 or 8 in dosage unit form.
Claim 12
Independent Claim
64 words
A method for the treatment of allergy in mammals, including man, characterized in administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR27## or a physiologically acceptable salt or an optical isomer thereof, in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR28##
Claim 13
Independent Claim
64 words
A method for the treatment of allergy in mammals, including man, characterized in administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR27## or a physiologically acceptable salt or an optical isomer thereof, in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR28##
Claim 14
Dependent Claim
40 words
A method for the treatment of allergy according to claim 10, characterized in administration to a host in need of such treatment of an effective amount of a compound according to any of claims 2, 3, 4, 5 or 6.
Claim 15
Independent Claim
38 words
A method for the treatment of bronchial asthma, characterized in administration to a host in need of such treatment of an effective amount of a compound according to any of claims 1, 2, 3, 4, 5 or 6.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-11-11 | 1984-05-12 | 1984-11-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-11-11 | 1988-05-12 | 1988-11-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-11-11 | 1992-05-12 | 1992-11-11 | $7700.00 | Window Closed / Lapsed |